Our findings that participants with known diagnosis of liver steatosis have higher T1-FF than those without, and that T1-FF correlates with markers of liver health (ALT and GGT) provide evidence that the mDIXON approach is effective in identifying the target pathology. This evidence concerns the gene GPT and Hepatic steatosis.